title: Serum concentration of bevacizumab after intravitreal injection in experimental branch retinal vein occlusion.
abstract: OBJECTIVE
  To compare the serum concentration of bevacizumab after intravitreal injection of bevacizumab (IVB) in an experimental model of branch retinal vein occlusion (BRVO) with control injections in albino rats.
  
  
  METHODS
  BRVO was created in one eye of each of the 24 albino rats. Another 24 rats served as controls. The BRVO was generated by argon laser photothrombosis after intravenous injection with Rose Bengal. Three days later, IVB (5 μl) was administered to both BRVO and control eyes. The serum concentration of bevacizumab was examined at baseline, 6 h, 1 day, 3 days, 7 days, 14 days, and 28 days after IVB.
  
  
  RESULTS
  At baseline, no serum bevacizumab was detected in either group. The serum concentration of bevacizumab reached a peak concentration at 1 day with 5,020 ± 1,602 ng/ml in the BRVO group and 4,103 ± 1,790 ng/ml in the control group (p < 0.001). The concentration decreased subsequently on days 3, 7, 14 and 28. The serum concentration of bevacizumab was significantly higher in BRVO rats up to 28 days after IVB.
  
  
  CONCLUSIONS
  The serum concentration of bevacizumab after IVB reached its peak on day 1 in both BRVO and control eyes. This value was significantly higher in BRVO rats than in control rats up to 28 days after intravitreal injection.
authors: Department of Ophthalmology, Chang Gung Memorial Hospital, Keelung, Taiwan, ROC.
authors: Lan-Hsin
authors: LH
authors: Chuang
authors: Wei-Chi
authors: WC
authors: Wu
authors: Ling
authors: L
authors: Yeung
authors: Nan-Kai
authors: NK
authors: Wang
authors: Yih-Shiou
authors: YS
authors: Hwang
authors: Kuan-Jen
authors: KJ
authors: Chen
authors: Jane Zea-Chin
authors: JZ
authors: Kuo
authors: Chi-Chun
authors: CC
authors: Lai
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000493:pharmacokinetics*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001682:Biological Availability; D004195:Disease Models, Animal; D006207:Half-Life; D058449:Intravitreal Injections; D051381:Rats; D017207:Rats, Sprague-Dawley; D012170:Retinal Vein Occlusion / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; C467498:vascular endothelial growth factor A, rat; D000068258:Bevacizumab